Literature DB >> 9009289

Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans.

S C Chen1, L C Wright, R T Santangelo, M Muller, V R Moran, P W Kuchel, T C Sorrell.   

Abstract

We recently identified phospholipase activity as a potential virulence factor of Cryptococcus neoformans. We have now defined the nature of the phospholipase activity produced by a clinical isolate of C. neoformans var. neoformans, under native conditions, by 1H and 31P nuclear magnetic resonance (NMR) spectroscopy and thin-layer chromatography (TLC) of radiolabelled substrates. Glycerophosphocholine was identified by NMR spectroscopy as the sole phospholipid degradation product of the reaction between substrate phosphatidylcholine (PC) and cryptococcal culture supernatants indicating the presence of phospholipase B (PLB). No lysophosphatidylcholine (lyso-PC) or products indicative of phospholipase C, phospholipase D, or other lipase activity were identified. Use of PC and lyso-PC containing radiolabelled acyl chains and separation of products by TLC confirmed the PLB and lysophospholipase (LPL) activities. Lysophospholipase transacylase (LPTA) activity was identified by the formation of radioactive PC from lyso-PC. Extracellular enzyme production was maximal after 6 to 10 h in fresh medium. Assay conditions were optimized for pH, linearity with time, enzyme concentration, and saturation by substrates to allow comparison with phospholipases from other organisms. LPL activity was 10- to 20-fold greater than PLB activity, with mean (+/- standard deviation) specific activities of 34.9 +/- 7.9 and 3.18 +/- 0.2 micromol of substrate hydrolyzed per min per mg of protein, respectively. The response of PLB to increasing substrate concentrations was bimodal, whereas inhibition of LPL and LPTA activities occurred at concentrations of substrate lyso-PC greater than 200 microM. Enzyme activities were stable at acid pH (3.8), with pH optima of 3.5 to 4.5. Activities were unchanged in the presence of exogenous serine protease inhibitors, divalent cations, and EDTA. We conclude that C. neoformans produces highly active extracellular PLB, LPL, and LPTA under native conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9009289      PMCID: PMC174609          DOI: 10.1128/iai.65.2.405-411.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Phospholipase activity in Candida albicans.

Authors:  M F Price; R A Cawson
Journal:  Sabouraudia       Date:  1977-07

3.  Substrate specificity of a highly purified phospholipase B from Penicillium notatum.

Authors:  K Saito; M Kates
Journal:  Biochim Biophys Acta       Date:  1974-11-18

4.  Factors affecting the phospholipase activity of Candida species in vitro.

Authors:  L P Samaranayake; J M Raeside; T W MacFarlane
Journal:  Sabouraudia       Date:  1984

5.  Phospholipase B from the plasma membrane of Saccharomyces cerevisiae. Separation of two forms with different carbohydrate content.

Authors:  W Witt; M E Schweingruber; A Mertsching
Journal:  Biochim Biophys Acta       Date:  1984-08-15

6.  Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice.

Authors:  K J Kwon-Chung; I Polacheck; T J Popkin
Journal:  J Bacteriol       Date:  1982-06       Impact factor: 3.490

7.  A microanalytical technique for the quantitative determination of twenty-four classes of brain lipids.

Authors:  M A Wells; J C Dittmer
Journal:  Biochemistry       Date:  1966-11       Impact factor: 3.162

8.  Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans.

Authors:  J C Rhodes; I Polacheck; K J Kwon-Chung
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

10.  Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.

Authors:  J F Breen; I C Lee; F R Vogel; H Friedman
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more
  39 in total

1.  Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B.

Authors:  M Gottfredsson; C J Jessup; G M Cox; J R Perfect; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans.

Authors:  Ranjini Ganendren; Fred Widmer; Vatsala Singhal; Christabel Wilson; Tania Sorrell; Lesley Wright
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter; Débora L Oliveira; Susana Frases; Kildare Miranda; Oscar Zaragoza; Mauricio Alvarez; Antonio Nakouzi; Marta Feldmesser; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2006-11-17

4.  Inactivation of the phospholipase B gene PLB5 in wild-type Candida albicans reduces cell-associated phospholipase A2 activity and attenuates virulence.

Authors:  Stephanie Theiss; Ganchimeg Ishdorj; Audrey Brenot; Marianne Kretschmar; Chung-Yu Lan; Thomas Nichterlein; Jörg Hacker; Santosh Nigam; Nina Agabian; Gerwald A Köhler
Journal:  Int J Med Microbiol       Date:  2006-06-06       Impact factor: 3.473

5.  Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.

Authors:  Fred Widmer; Lesley C Wright; Daniel Obando; Rosemary Handke; Ranjini Ganendren; David H Ellis; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

7.  Selection of optimal host strain for molecular pathogenesis studies on Cryptococcus gattii.

Authors:  Sudha Chaturvedi; Ping Ren; Srinivas D Narasipura; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2005-10       Impact factor: 2.574

8.  Changes in glucosylceramide structure affect virulence and membrane biophysical properties of Cryptococcus neoformans.

Authors:  Shriya Raj; Saeed Nazemidashtarjandi; Jihyun Kim; Luna Joffe; Xiaoxue Zhang; Ashutosh Singh; Visesato Mor; Desmarini Desmarini; Julianne Djordjevic; Daniel P Raleigh; Marcio L Rodrigues; Erwin London; Maurizio Del Poeta; Amir M Farnoud
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-09-01       Impact factor: 3.747

9.  The transcriptional response of Cryptococcus neoformans to ingestion by Acanthamoeba castellanii and macrophages provides insights into the evolutionary adaptation to the mammalian host.

Authors:  Lorena da S Derengowski; Hugo Costa Paes; Patrícia Albuquerque; Aldo Henrique F P Tavares; Larissa Fernandes; Ildinete Silva-Pereira; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2013-03-22

10.  Characterization of the PMT gene family in Cryptococcus neoformans.

Authors:  Sven D Willger; Joachim F Ernst; J Andrew Alspaugh; Klaus B Lengeler
Journal:  PLoS One       Date:  2009-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.